211 related articles for article (PubMed ID: 37528303)
1. Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort.
Zwart K; van der Baan FH; Punt CJA; Wensink GE; Bolhuis K; Laclé MM; van Grevenstein WMU; Hagendoorn J; de Hingh IH; Koopman M; Vink G; Roodhart J
Ann Surg Oncol; 2023 Oct; 30(11):6762-6770. PubMed ID: 37528303
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of Lynch syndrome, BRAF
Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
[TBL] [Abstract][Full Text] [Related]
3. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
[TBL] [Abstract][Full Text] [Related]
4. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
[No Abstract] [Full Text] [Related]
5. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T
Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130
[TBL] [Abstract][Full Text] [Related]
7. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
8. Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer.
van der Heide DM; Turaga KK; Chan CHF; Sherman SK
J Surg Res; 2021 Oct; 266():104-112. PubMed ID: 33989889
[TBL] [Abstract][Full Text] [Related]
9. Different surgical outcome and follow-up status between dMMR and pMMR colorectal cancer patients who fulfilled with Amsterdam-II criteria.
Sun CY; Chiang JM; Chen TC; Hung HY; You JF
World J Surg Oncol; 2020 Aug; 18(1):195. PubMed ID: 32767993
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
Li JY; Park HS; Huang GS; Young MR; Ratner E; Santin A; Damast S
Gynecol Oncol; 2021 Dec; 163(3):557-562. PubMed ID: 34602287
[TBL] [Abstract][Full Text] [Related]
11. A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research.
Wensink E; Bond M; Kucukkose E; May A; Vink G; Koopman M; Kranenburg O; Roodhart J
Cancer Treat Rev; 2021 Apr; 95():102174. PubMed ID: 33721596
[TBL] [Abstract][Full Text] [Related]
12. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab.
Saberzadeh-Ardestani B; Jones JC; Hubbard JM; McWilliams RR; Halfdanarson TR; Shi Q; Sonbol MB; Ticku J; Jin Z; Sinicrope FA
JAMA Netw Open; 2023 Feb; 6(2):e230400. PubMed ID: 36811859
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
14. Intertumoral Heterogeneity of CD3
Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA
Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.
Rohr UP; Herrmann P; Ilm K; Zhang H; Lohmann S; Reiser A; Muranyi A; Smith J; Burock S; Osterland M; Leith K; Singh S; Brunhoeber P; Bowermaster R; Tie J; Christie M; Wong HL; Waring P; Shanmugam K; Gibbs P; Stein U
Ann Oncol; 2017 Aug; 28(8):1869-1875. PubMed ID: 28460000
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.
Antill Y; Kok PS; Robledo K; Yip S; Cummins M; Smith D; Spurdle A; Barnes E; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Andrews J; Stockler MR; Mileshkin L;
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103352
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J; Ke G; Bi R; Wu X
J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
[TBL] [Abstract][Full Text] [Related]
18. Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.
Wensink GE; Elferink MAG; May AM; Mol L; Hamers PAH; Bakker SD; Creemers GJ; de Groot JWB; de Klerk GJ; Haberkorn BCM; Haringhuizen AW; Hoekstra R; Hunting JCB; Kerver ED; Mathijssen-van Stein D; Polée MB; Pruijt JFM; Quarles van Ufford-Mannesse P; Radema S; Rietbroek RC; Simkens LHJ; Tanis BC; Ten Bokkel Huinink D; Tjin-A-Ton MLR; Tromp-van Driel CS; Troost MM; van de Wouw AJ; van den Berkmortel FWPJ; van der Pas AJM; van der Velden AMT; van Dijk MA; van Dodewaard-de Jong JM; van Druten EB; van Voorthuizen T; Jan Veldhuis G; Verheul HMW; Vestjens HJHMJ; Vincent J; Kranenburg OW; Punt CJA; Vink GR; Roodhart JML; Koopman M
Br J Cancer; 2021 Jan; 124(2):399-406. PubMed ID: 33046804
[TBL] [Abstract][Full Text] [Related]
19. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
[TBL] [Abstract][Full Text] [Related]
20. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.
Venderbosch S; Nagtegaal ID; Maughan TS; Smith CG; Cheadle JP; Fisher D; Kaplan R; Quirke P; Seymour MT; Richman SD; Meijer GA; Ylstra B; Heideman DA; de Haan AF; Punt CJ; Koopman M
Clin Cancer Res; 2014 Oct; 20(20):5322-30. PubMed ID: 25139339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
